WO2007007182A3 - Solid and liquid dosage forms of an antiepileptic agent - Google Patents

Solid and liquid dosage forms of an antiepileptic agent Download PDF

Info

Publication number
WO2007007182A3
WO2007007182A3 PCT/IB2006/001949 IB2006001949W WO2007007182A3 WO 2007007182 A3 WO2007007182 A3 WO 2007007182A3 IB 2006001949 W IB2006001949 W IB 2006001949W WO 2007007182 A3 WO2007007182 A3 WO 2007007182A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage forms
solid
liquid dosage
antiepileptic agent
relates
Prior art date
Application number
PCT/IB2006/001949
Other languages
French (fr)
Other versions
WO2007007182A2 (en
Inventor
Umesh Setty
Mohinder Paul Pakhetra
Ashish Gogia
Kishor Deo
Uttam Kumar Ray
Srikanth Guntupalli
Sivakumaran Meenakshisunderam
Original Assignee
Aurobindo Pharma Ltd
Umesh Setty
Mohinder Paul Pakhetra
Ashish Gogia
Kishor Deo
Uttam Kumar Ray
Srikanth Guntupalli
Sivakumaran Meenakshisunderam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurobindo Pharma Ltd, Umesh Setty, Mohinder Paul Pakhetra, Ashish Gogia, Kishor Deo, Uttam Kumar Ray, Srikanth Guntupalli, Sivakumaran Meenakshisunderam filed Critical Aurobindo Pharma Ltd
Publication of WO2007007182A2 publication Critical patent/WO2007007182A2/en
Publication of WO2007007182A3 publication Critical patent/WO2007007182A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Abstract

The present invention relates to oral dosage forms of an antiepileptic agent. More particularly, the present invention relates to oral dosage forms of oxcarbazepine or its pharmaceutically acceptable salts. The present invention also relates to a process for the preparation of oral dosage forms of oxcarbazepine or its pharmaceutically acceptable salts.
PCT/IB2006/001949 2005-07-08 2006-07-05 Solid and liquid dosage forms of an antiepileptic agent WO2007007182A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
IN905/CHE/2005 2005-07-08
IN905CH2005 2005-07-08
IN995/CHE/2005 2005-07-25
IN995CH2005 2005-07-25
IN1935/CHE/2005 2005-12-27
IN1935CH2005 2005-12-27
IN311CH2006 2006-02-24
IN311/CHE/2006 2006-02-24

Publications (2)

Publication Number Publication Date
WO2007007182A2 WO2007007182A2 (en) 2007-01-18
WO2007007182A3 true WO2007007182A3 (en) 2007-08-23

Family

ID=37564047

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001949 WO2007007182A2 (en) 2005-07-08 2006-07-05 Solid and liquid dosage forms of an antiepileptic agent

Country Status (1)

Country Link
WO (1) WO2007007182A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107987618A (en) * 2013-03-29 2018-05-04 罗盖特公司 Film-forming composition for the coating of solid form

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2029118A2 (en) * 2006-01-31 2009-03-04 Teva Pharmaceutical Industries, Inc. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
AU2007242062A1 (en) * 2006-04-21 2007-11-01 Alphapharm Pty Ltd Pharmaceutical compositions of oxcarbazepine with a median particle size of 15 to 30 microns
WO2008037044A1 (en) * 2006-09-27 2008-04-03 Medley S.A. Indústria Farmacêutica Oxcarbazepine-containing oral formulation and a process to obtain the same
US20130040939A1 (en) * 2009-09-10 2013-02-14 Bial - Portela & Ca, S.A. Oral Suspension Formulations of Esclicarbazepine Acetate
AR125970A1 (en) * 2021-05-28 2023-08-30 Sk Biopharmaceuticals Co Ltd AQUEOUS SUSPENSION FORMULATIONS FOR ORAL ADMINISTRATION COMPRISING A CARBAMATE COMPOUND
CN115487145B (en) * 2022-10-10 2023-09-01 上海奥科达医药科技股份有限公司 Oxcarbazepine oral suspension and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0435826A1 (en) * 1989-12-27 1991-07-03 Ciba-Geigy Ag Intravenous solutions for epilepsy
WO2002094774A2 (en) * 2001-05-18 2002-11-28 Ranbaxy Laboratories Limited Oxcarbazepine dosage forms
US20030190361A1 (en) * 1997-02-14 2003-10-09 Burkhard Schlutermann Oxacarbazepine film-coated tablets
EP1437127A1 (en) * 1999-12-20 2004-07-14 Novartis AG Suspension comprising oxcarbazepine
WO2006046105A1 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Oxcarbazepine dosage forms

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0435826A1 (en) * 1989-12-27 1991-07-03 Ciba-Geigy Ag Intravenous solutions for epilepsy
US20030190361A1 (en) * 1997-02-14 2003-10-09 Burkhard Schlutermann Oxacarbazepine film-coated tablets
EP1437127A1 (en) * 1999-12-20 2004-07-14 Novartis AG Suspension comprising oxcarbazepine
WO2002094774A2 (en) * 2001-05-18 2002-11-28 Ranbaxy Laboratories Limited Oxcarbazepine dosage forms
WO2006046105A1 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Oxcarbazepine dosage forms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHICHT S ET AL: "PHARMCOKINETICSOF OXCARBAZEPINE IN THE DOG", JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 19, no. 1, February 1996 (1996-02-01), pages 27 - 31, XP000998533, ISSN: 0140-7783 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107987618A (en) * 2013-03-29 2018-05-04 罗盖特公司 Film-forming composition for the coating of solid form

Also Published As

Publication number Publication date
WO2007007182A2 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
AP2303A (en) d-Crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it.
AP2006003521A0 (en) Y-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it.
SI1695710T1 (en) Crystalline form beta-d of the chlorohydrate of ivabradine, process for its preparation and pharmaceutical compositions containing it
ME01394B (en) Crystalline form gamma-d of the chlorohydrate of ivabradine, process for its preparation and pharmaceutical compositions containing it
WO2009084024A3 (en) A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
AP2405A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms.
SI1598333T1 (en) Process for the preparation of (1S)-4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane, acid addition salts thereof and its use for the synthesis of ivabradine and for its pharmaceutically acceptable acid addition salts
WO2006131591A3 (en) An entacapone-containing oral dosage form
PL1752443T3 (en) New crystalline form V of agometaline, the process for its preparation and the pharmaceutical compositions containing it
WO2008044243A3 (en) Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
IL199472A0 (en) Non-effervescent, orally disintegrating solid pharmaceutical dosage forms, processes for the preparation of the same and uses thereof
SI2210872T1 (en) New crystalline form iii of agometalin, the process for its preparation and pharmaceutical compositions containing it
MY144857A (en) Phamaceutical composition comprising amlodipine and losartan
WO2007144169A3 (en) Entacapone-derivatives
WO2007007182A3 (en) Solid and liquid dosage forms of an antiepileptic agent
PL1846376T3 (en) Method for preparation of 10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2003026610A3 (en) Process for the preparation of fast dissolving dosage form
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
NO20064783L (en) Solution tablets with licarbazepine
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
WO2007144699A3 (en) Process for the preparation of alfuzosin
WO2008094054A3 (en) 6, 8-dichlorchroman-3-yl-l, 3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders
WO2009013594A3 (en) Process for the preparation of controlled-release solid formulations containing oxcarbazepine, and formulations obtainable by said process
WO2007110765A3 (en) Processes for the preparation of octreotide

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06765636

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06765636

Country of ref document: EP

Kind code of ref document: A2